Join to View Full Profile
1021 Morehead Medical DrSte ACharlotte, NC 28204
Phone+1 980-442-2000
Dr. Hu is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Lymphoma and apheresis attending at Levine Cancer Institute/Atrium Health. Board certified in Hematology, Medical Oncology, and Internal Medicine
Education & Training
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2014 - 2017
Vanderbilt University Medical CenterResidency, Internal Medicine, 2011 - 2014
University of California San Francisco School of MedicineClass of 2011
Certifications & Licensure
NC State Medical License 2017 - 2026
TX State Medical License 2015 - 2017
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Conquer Cancer Merit Award ASCO, Conquer Cancer Foundation, 2016
Clinical Trials
- Safety and Pharmacokinetics of Multiple Dose of YC-6 in Healthy Subjects Start of enrollment: 2016 Dec 01
- Study of Zanubrutinib (BGB-3111) in Participants With Marginal Zone Lymphoma Start of enrollment: 2019 Feb 19
Publications & Presentations
PubMed
- Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory/Relapsed Large B-Cell Lymphoma: Primary Results of the Phase III SUNMO Trial.Lihua E Budde, Huilai Zhang, Won-Seog Kim, Dai Maruyama, Eduardo M Rego
Journal of Clinical Oncology. 2025-10-02 - 4 citationsSubgroup analysis of older patients ≥60 years with diffuse large B-cell lymphoma in the phase 3 POLARIX study.Bei Hu, Patrick M Reagan, Laurie H Sehn, Jeff P Sharman, Mark Hertzberg
Blood Advances. 2025-05-27 - 2 citationsEvaluation of the Impact of Monitoring for Tumor Lysis During Venetoclax Ramp-Up in Chronic Lymphocytic Leukemia in Routine Clinical Practice.Nilanjan Ghosh, Ashley Matusz-Fisher, Rupali Bose, Danielle Boselli, Gray Magee
JCO Oncology Practice. 2025-05-01
Journal Articles
- De Novo CD5+ diffuse large B cell lymphoma: clinic characterististics and clinical outcomes in the Rituximab era2. Hu B, Nastoupil LJ, Westin JR, Logavi S, Thakral B, Fayad LE, Hagemeister G, Neelapu S, Samaniego F, Lee HJ, Wang ML, Fanale M, Fowler N, Oki Y, Leukemia and Lymphoma, 9/18/2019
- Standardizing opioid prescribing practices for cancer-related pain via a novel interactive documentation template at a public hospital3. Nusrat M, Parkes A, Kieser R, Hu B, Farhat D, Rieber A, Ma H, Journal of Oncology Practice, 6/21/2019
- A tale of two eras: the story of autologous stem cell transplantation with and without thiotepa for primary central nervous system lymphomaHu B, Biology of Blood and Marrow Transplantation, 5/2019
- Join now to see all
Press Mentions
DLBCL: Novel Drug Combo Boosts Survival in Older Adult PatientsApril 10th, 2025
Downregulation of SENP1 Suppresses LPS-Induced Macrophage Inflammation by Elevating Sp3 SUMOylation and Disturbing Sp3-NF-κB InteractionNovember 15th, 2020
High Use of Oncology Nurse Navigators Showed Similar Clinical Outcomes for White, Nonwhite Patients with DLBCLDecember 12th, 2019
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
